You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Pregabalin in severe burn injury pain: A double-blind, randomised placebo-controlled trial
|
|---|---|
| Published in |
Pain (03043959), March 2011
|
| DOI | 10.1016/j.pain.2011.01.055 |
| Pubmed ID | |
| Authors |
Paul Gray, Julie Kirby, Maree T. Smith, Peter J. Cabot, Bronwyn Williams, James Doecke, Tess Cramond |
| Abstract |
This randomised, double-blind, placebo-controlled trial assessed the efficacy and tolerability of pregabalin to alleviate the neuropathic component of moderate to severe burn pain. Patients aged 18 to 65 years admitted to a burns unit with a 5% or greater total body surface area burn injury were screened to participate in the trial. Using the Neuropathic Pain Scale (NPS), patients scoring 4 or higher on 'hot' pain or 'sharp' pain were invited to participate. Consenting patients were randomly assigned to receive pregabalin or placebo for 28 days with individual dose titration commencing at 75 mg twice daily to a maximum pregabalin dose of 300 mg twice daily. The primary outcome measure was the patients' daily response to the sharp and hot pain of the NPS. Secondary outcome measures included the remaining elements of the NPS, daily opioid requirement, length of hospital stay, pain at 6 months, and side effects of nausea, vomiting, drowsiness and giddiness. For patients administered pregabalin, the primary outcome measures hot (P = .01) and sharp (P = .04) pain were significantly reduced compared with those in patients administered placebo. Secondary outcome measures of itch, unpleasantness, surface pain, and procedural pain were significantly lower (P < .05) in the pregabalin group. Adverse effects were uncommon, with no difference between the treatment groups. There was no significant difference between the pregabalin and placebo treatment groups with respect to opioid consumption, duration of hospital stay, or pain at 6 months. Pregabalin was efficacious and well tolerated in patients after severe burn injury and whose pain was characterised by features of acute neuropathic pain. In this study, pregabalin was well tolerated and significantly reduced several elements of the neuropathic pain scale including hot pain, unpleasantness of the pain, surface pain, and itch, and also significantly reduced procedural pain. |
Mendeley readers
The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Unknown | 147 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 15% |
| Other | 16 | 11% |
| Student > Master | 16 | 11% |
| Student > Bachelor | 12 | 8% |
| Student > Ph. D. Student | 9 | 6% |
| Other | 39 | 26% |
| Unknown | 34 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 70 | 47% |
| Psychology | 9 | 6% |
| Nursing and Health Professions | 7 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Neuroscience | 3 | 2% |
| Other | 16 | 11% |
| Unknown | 38 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2017.
All research outputs
#7,355,930
of 25,374,647 outputs
Outputs from Pain (03043959)
#3,269
of 6,470 outputs
Outputs of similar age
#38,362
of 119,058 outputs
Outputs of similar age from Pain (03043959)
#34
of 82 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 6,470 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.1. This one is in the 47th percentile – i.e., 47% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 119,058 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 82 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.